177Lu-DOTATATE in advanced neuroendocrine neoplasms of different locations – Data from 552 cases in the SEPTRALU registry

#3779

Introduction: Peptide receptor radionuclide therapy (PRRT) is a therapeutic strategy selected via a marker, somatostatin receptor (SSTRs) expression, with activity in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Its role in tumor sites outside the digestive tract remains unclear.

Aim(s): To evaluate the efficacy and safety of 177Lu-DOTATATE in NENs depending on the tumor location.

Materials and methods: Patients (n=522) were enrolled in the Spanish SEPTRALU registry of advanced NENs overexpressing SSTRs and treated at 24 centers. The standard protocol consisted of four cycles of 177Lu-DOTATATE 7.4 GBq iv every 8 weeks.

Conference:

Presenting Author:

Authors: Mitjavila Casanovas M, Carmona-Bayonas A, Bello P, de Matias Leralta J, Garcia Burillo A,

Keywords: 177Lu-DOTATATE, lung, neuroendocrine tumor, PRRT, pheochromocytoma, radionuclide therapy,